Participants
cancer, cardiovascular disease
CARDIOVASCULAR DISEASE, CANCER, MALIGNANCIES, ONCOLOGY, DISEASES
This single-center study was conducted in Fujian cancer hospital, Fuzhou, China. Patients with newly pathologically confirmed NPC, age 18 to 70 years, with Eastern Cooperative Oncology Group performance status (ECOG PS) between 0 and 1, who provided written consent to participate in the study, cooperated with regular follow-up and complied with the experimental requirements were included in this study. Exclusion criteria were as follows: (1) patients with severe cardiovascular disease or other underlying conditions that affect the implementation of standardized treatment for NPC; (2) patients with previous diseases of thyroid, hypothalamus and pituitary; (3) patients have received prior chemotherapy or radiotherapy of the head and neck; (4) patients with other malignancies. All participants signed a written informed consent form.